⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28634026 | 0.93 | TP53 (0.42) | — | |
| SCHEMBL761168 | 0.92 | — | — | |
| SCHEMBL8458992 | 0.89 | TP53 (0.50) | — | |
| SCHEMBL40973 | 0.89 | — | — | |
| SCHEMBL9493197 | 0.89 | TP53 (0.50) | — | |
| SCHEMBL8392719 | 0.89 | TP53 (0.50) | — | |
| SCHEMBL9815690 | 0.89 | TP53 (0.50) | — | |
| SCHEMBL20004088 | 0.85 | TP53 (0.37) | — | |
| SCHEMBL3182655 | 0.84 | — | — | |
| SCHEMBL8910860 | 0.84 | TP53 (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240368063-A1 | PREPARATION METHOD, INTERMEDIATE COMPOUNDS, AND SYNTHESIS METHOD FOR A CLASS OF ANTHRACENE-DERIVED TOXINS IN ORGANIC CHEMISTRY | WUYAN PHARMACEUTICAL TECHNOLOGY (SHANGHAI) CO., LTD (CN) | 2024-11-07 | — | — | US | claimed |
| EP-2114980-B1 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARM INC (US) | 2012-06-27 | — | — | EP | claimed |
| US-20120142617-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-07 | — | — | US | claimed |
| JP-2011525171-A | — | — | 2011-09-15 | — | — | JP | claimed |
| US-7994139-B2 | Antiviral therapeutic agents | BIOCRYST PHARMACEUTICALS, INC. (US) | 2011-08-09 | — | — | US | claimed |
| EP-2265275-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BioCryst Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | claimed |
| WO-2010036407-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2010-04-01 | — | — | WO | claimed |
| US-20100015094-A1 | ANTIVIRAL NUCLEOSIDE ANALOGS | WILMINGTON TRUST, NATIONAL ASSOCIATION | 2010-01-21 | — | — | US | claimed |
| EP-2114980-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | Biocryst Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | claimed |
| WO-2009111653-A2 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-11 | — | — | WO | claimed |
| US-20090227524-A1 | ANTIVIRAL THERAPEUTIC AGENTS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2009-09-10 | — | — | US | claimed |
| US-20080300200-A1 | Therapeutic Furopyrimidines and Thienopyrimidines | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-12-04 | — | — | US | claimed |
| WO-2008089105-A2 | ANTIVIRAL NUCLEOSIDE ANALOGS | BIOCRYST PHARMACEUTICALS, INC. (US) | 2008-07-24 | — | — | WO | claimed |
| EP-1814561-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | Biocryst Pharmaceuticals, Inc. (US) | 2007-08-08 | — | — | EP | claimed |
| WO-2006050161-A2 | THERAPEUTIC FUROPYRIMIDINES AND THIENOPYRIMIDINES | BIOCRYST PHARMACEUTICALS, INC. (US) | 2006-05-11 | — | — | WO | claimed |
| WO-2025022124-A2 | METHODS FOR DEPOLYMERISING AND REPOLYMERISING | Epoch Biodesign Ltd (GB) | 2025-01-30 | — | — | WO | disclosed |
| EP-3080123-B1 | IMIDAZOPYRIDINE DERIVATIVES AS MODULATORS OF TNF ACTIVITY | UCB Biopharma SRL (BE) | 2020-06-17 | — | — | EP | disclosed |
| EP-0452729-A1 | Process for preparing substituted cyclobutanes | BRISTOL-MYERS SQUIBB COMPANY (US) | 1991-10-23 | — | — | EP | disclosed |
| US-5020598-A | Injecting mixture of polyalcohols and cement to make fluid-tight sealing | SHELL OIL COMPANY (US) | 1991-06-04 | — | — | US | disclosed |
| US-4255301-A | HEAT RESISTANCE, PHOTOSTABILITY | ARGUS CHEMICAL CORPORATION (US) | 1981-03-10 | — | — | US | disclosed |